News

Opposition to Bristol-Myers Squibb’s $74 billion acquisition of Celgene could endanger the deal, and the whole situation is ‘somewhat unprecedented’

Opposition to pharmaceutical company Bristol-Myers Squibb’s $US74 billion acquisition of Celgene is growing, and could endanger the deal. The acquisition is facing pushback from Bristol-Myers’ second-largest shareholder, the investment firm Wellington Management, and from activist investor Starboard Value. This level of uncertainty for such a large deal is “somewhat unprecedented” […]
Opposition to Bristol-Myers Squibb’s $74 billion acquisition of Celgene could endanger the deal, and the whole situation is ‘somewhat unprecedented’